This Long-Term Winning Stock Is in a Growth Market and Just Hit New 3-Year Highs
-
BioLife Solutions (BLFS) is a leader in advanced preservation solutions for cellular matter, with strong technical momentum and a recent 3-year high.
-
Shares are up nearly 60% over the past year.
-
BLFS maintains a 100% “Buy” technical rating and a Trend Seeker “Buy” signal.
-
Analyst sentiment is mixed, with most rating BLFS a “Hold” and price targets below current levels.
Today’s Featured Stock
Valued at $1.85 billion, BioLife Solutions (BLFS) has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation, and storage.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. BLFS checks those boxes. The Trend Seeker issued a new “Buy” signal on Sept. 15. The stock has gained 5.41% since that signal.
More News from Barchart
Barchart’s Technical Indicators for BioLife Solutions
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
BioLife Solutions hit a 3-year high of $38.49 on Sept. 4 23.
-
BioLife has a Weighted Alpha of 76.25.
-
BLFS has a 100% “Buy” opinion from Barchart.
-
The stock has gained 59.1% over the past 52 weeks.
-
BioLife has its Trend Seeker “Buy” signal intact.
-
The stock recently traded at $38.20 with a 50-day moving average of $34.51.
-
BLFS had 4 highs and gained 3.15% in the last month.
-
60-month beta of 1.91.
-
Relative Strength Index (RSI) is at 68.14.
-
There’s a technical support level around $37.24.
Don’t Forget the Fundamentals
-
$1.85 billion market capitalization.
-
237.95x trailing price-earnings ratio.
-
Revenue is projected to grow by 19.76% this year and another17.03% next year.
-
Earnings are estimated to increase by 91.86% this year and an additional 32.00% next year.
Analyst and Investor Sentiment on BioLife Solutions
-
The Wall Street analysts followed by Barchart give the stock 1 “Strong Buy” and 9 “Hold” opinions with price targets from $31 to $34.
-
Morningstar thinks the stock is 6% overvalued with a fair value of $35.39.
-
CFRA’s MarketScope rates the stock as “Hold.”
-
6,220 investors are following the stock on Seeking Alpha, which rates it a “Hold.”
-
TipRanks’ analysts’ price target is $31.00.
-
Short interest is 8.03% of the float with 4.81 days to cover the float.
The Bottom Line on BioLife Solutions
Preserving lab and medical samples is a growing market and this stock could be a long-term winner. If you have it, hold it, but have an exit point in mind.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio, it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com